Cannabis Helped Him Quit Opioids. His State Still Calls It a Crime.

A recovery story published this week underscores the ongoing tension between America's opioid epidemic and cannabis prohibition, as one patient describes using marijuana to end his dependency on prescription painkillers—in a state where doing so remains illegal.

The anonymous account, shared through High Times, details a years-long struggle with opioid dependency that began with a legitimate prescription. The patient eventually turned to cannabis as an exit strategy, finding it effective where other interventions had failed.

"The drug that almost destroyed me was legal," the patient wrote. "The one that helped me walk away was not."

The story arrives as federal data shows opioid-related deaths exceeded 80,000 in 2023, while 24 states maintain full cannabis prohibition. That disconnect has drawn increased attention from researchers and policymakers examining alternatives to traditional addiction treatment.

The Research Gap

Studies on cannabis as an opioid substitution therapy remain limited due to marijuana's Schedule I classification under federal law. A 2022 analysis published in the Journal of Pain Research found that medical cannabis patients reported a 64% reduction in opioid use, but researchers noted the need for larger controlled trials.

Dr. Kevin Hill, an addiction psychiatrist at Beth Israel Deaconess Medical Center, has called for expanded research access. "We have preliminary evidence suggesting cannabis may help some patients reduce opioid use," Hill said in a recent interview with MJBizDaily. "But we can't make definitive clinical recommendations without proper studies."

The National Institute on Drug Abuse allocated $3.8 million for cannabis-opioid research in 2023, up from $1.2 million in 2020. Yet bureaucratic hurdles continue to slow progress, with researchers citing delays of 12-18 months simply to obtain federal approval for cannabis studies.

State-Level Contradictions

Twelve medical cannabis states now list opioid use disorder as a qualifying condition, including New York, Pennsylvania, and Illinois. These programs operate in legal gray areas, as federal guidelines still classify cannabis as having "no accepted medical use."

Patient advocacy groups have documented thousands of similar stories through surveys and testimonials. Americans for Safe Access reported in 2023 that 37% of medical cannabis patients cite pain management and opioid reduction as primary reasons for use.

But in the 24 states without legal cannabis programs, patients face potential criminal charges for what they describe as life-saving treatment. Possession penalties range from misdemeanors to felonies depending on jurisdiction, with some states imposing mandatory minimum sentences.

What Policy Experts Say

The disconnect between opioid crisis rhetoric and cannabis policy has not gone unnoticed in Washington. During recent congressional hearings on the fentanyl crisis, several lawmakers raised questions about cannabis research barriers.

"We're spending billions on the opioid epidemic while simultaneously blocking research into potential alternatives," said Rep. Earl Blumenauer (D-OR) during a House committee hearing in March. "That makes no sense."

The Department of Health and Human Services recommended rescheduling cannabis to Schedule III in August 2023, which would ease some research restrictions. The Drug Enforcement Administration has yet to act on that recommendation, now eight months old.

Moving Forward

Advocacy organizations are pushing for federal policy changes that would allow broader cannabis research and protect patients using marijuana for opioid dependency. The Medical Cannabis Research Act, reintroduced in January 2024, would streamline approval processes for cannabis studies.

Meanwhile, stories like the one published this week continue to accumulate—patients making illegal choices in pursuit of recovery, caught between a deadly epidemic and outdated prohibition.

The next congressional hearing on cannabis rescheduling is expected in June, though no formal date has been announced. Patient advocates plan to submit testimony highlighting cannabis use in addiction treatment.

---

This article is based on original reporting by hightimes.com.